Pharmaceutical Market Europe • November 2024 • 36

APPOINTMENTS

Pfizer

John McGinley

Image

Pfizer has appointed John McGinley as UK managing director and country president. McGinley, who has been acting as interim UK country president, brings extensive experience to the role. He has held positions of increasing responsibility over more than a decade at Pfizer and has most recently been leading the company’s UK primary care division, a role that has lately involved supporting the Department of Health and Social Care, the UK Health Security Agency and the NHS with the implementation of a national immunisation programme. His previous roles at Pfizer have also included COVID-19 mRNA vaccines and anti-viral lead UK, and hospital business unit lead and managing director Germany. McGinley is also a member of the Association of the British Pharmaceutical Industry’s board. He succeeds Susan Rienow, who is now global Chief Marketing Officer.

Innate Pharma

Jonathan Dickinson

Image

Innate Pharma has appointed Jonathan Dickinson as chief executive officer and chairman of the executive board. Dickinson most recently served as executive vice president and general manager, Europe at Incyte. Prior to this, he held several senior positions at ARIAD Pharmaceuticals, Bristol Myers Squibb and Roche, after beginning his career at Novartis.

Biogen

Daniel Quirk

Image

Biogen has appointed Daniel Quirk as chief medical officer and head of medical affairs. Quirk was most recently senior vice president of worldwide medical affairs for immunology and neuroscience at Bristol Myers Squibb. Earlier in his career, he served in leadership positions at Pfizer, including as vice president and medical category lead for inflammation and immunology, emerging markets.

Novavax

Ruxandra Draghia-Akli

Image

Novavax has appointed Ruxandra Draghia-Akli as executive vice president and head of research and development. Draghia-Akli has more than 20 years of experience in vaccines and public health. She most recently served as global head of global public health research and development at Johnson & Johnson, and was previously vice president, global vaccines at Merck.

Mosaic Therapeutics

Barry Davies

Image

Mosaic Therapeutics has appointed Barry Davies as chief scientific officer. Davies joins the company with over 25 years of experience in drug discovery. He spent almost two decades at AstraZeneca, where he most recently held the position of senior director, global project leader. He was also previously senior director, clinical and translational scientific alliance at AstraZeneca.

Moderna

Abbas Hussain

Moderna has appointed Abbas Hussain to its board of directors. Hussain has more than 35 years of commercial leadership and operating experience in healthcare and was most recently chief executive officer of Vifor Pharma. Prior to this, he served in various leadership roles at GSK, including as global president, pharmaceuticals and vaccines.

Myricx Bio

Paolo Paoletti

Myricx Bio has appointed Paolo Paoletti as an independent non-executive director. Paoletti joins the board with extensive experience in the life sciences sector. He was the first president of GSK oncology and previously served as chief executive officer of GammaDelta Therapeutics. He has also held roles at Eli Lilly and the University of Pisa.

Curve Therapeutics

Rab Prinjha

Curve Therapeutics has appointed Rab Prinjha as chief research and development officer. Prinjha brings more than two decades of industry experience to the role. He joins Curve from GSK, where he served in a variety of roles, most recently as head of the company’s immunology research unit and immunology network sponsor.

Commit Biologics

Mikkel Wandahl Pedersen

Commit Biologics has appointed Mikkel Wandahl Pedersen as chief scientific officer. Pedersen has over two decades of experience in immuno-oncology and autoimmune disease drug discovery and development, and joins Commit from Nykode Therapeutics, where he also served as chief scientfic officer. He previously held the same role at Symphogen.